Shopping Cart 0
Cart Subtotal
USD 0

Saniona AB (SANION) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Saniona AB (Saniona), formerly Aniona is a research and development company that develops drugs for central nervous system diseases, autoimmune diseases, metabolic diseases and pain management. The company's pipeline products include tesofensine, a triple monoamine reuptake inhibitor, which is used to treat obesity and type 2 diabetes; tesomet, a fix-dosed combination of tesofensine and metoprolol for the treatment of type 2 diabetes and prader-willi syndrome; and NS2359, a triple monoamine reuptake inhibitor, which is used to treat cocaine addiction. It also develops CAD-1883, a program for treatment of ataxia and essential tremors. The company conducts research on three classes of ion channels including GABAA receptors, nicotinic acetylcholine receptors and potassium channels. Saniona is headquartered in Ballerup, Denmark.

Saniona AB (SANION)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Saniona AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Saniona AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Saniona AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Saniona AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Saniona AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Saniona AB, Pharmaceuticals & Healthcare, Deal Details 11

Asset Purchase 11

Saniona Acquires ACR325 and ACR343 Drugs from NeuroSearch 11

Saniona Acquires Assets from NeuroSearch 12

Saniona Acquires Technical Platforms from NeuroSearch 13

Aniona Acquires Portfolio of Preclinical Assets from NeuroSearch 14

Partnerships 15

Boehringer Ingelheim Enters into Research Agreement with Saniona 15

Saniona Enters into Agreement with Productos Medix 16

Saniona Enters into Agreement with Syngene 17

Saniona Extends R&D Agreement with Ataxion 18

Equity Offering 19

Initiator Pharma to Raise USD2.4 Million in Rights Offering of Units 19

Scandion Oncology Raises USD0.3 Million in Private Placement of Shares 20

Saniona Raises USD4 Million in Private Placement of Shares 21

Scandion Oncology Spins-Off from Saniona 22

Initiator Pharma Raises USD2.3 Million in Rights Offering of Shares 23

Initiator Pharma Spins Out from Saniona 24

Saniona Completes IPO For USD 2.6 Million 25

Debt Offering 26

Saniona to Raise USD8.7 Million in Private Placement of Bonds 26

Asset Transactions 27

Ataxion Acquires Ataxia Program from Saniona 27

Saniona AB-Key Competitors 28

Saniona AB-Key Employees 29

Saniona AB-Locations And Subsidiaries 30

Head Office 30

Other Locations & Subsidiaries 30

Recent Developments 31

Financial Announcements 31

Aug 22, 2018: Saniona publishes its interim report for the second quarter 2018 31

May 24, 2018: Saniona publishes its interim report for the first quarter 2018 32

Feb 21, 2018: Saniona publishes its year-end report for 2017 33

Nov 15, 2017: Saniona publishes its interim report for the third quarter 2017 34

Aug 23, 2017: Saniona publishes its interim report for the second quarter 2017 35

Feb 21, 2017: Saniona publishes year-end report for 2016 36

Corporate Communications 37

Dec 22, 2017: Saniona: The Nomination Committee of Saniona Proposes Election of Two Additional Members of the Board of Directors 37

May 31, 2017: Saniona approved for listing on Nasdaq Stockholm's main market 39

Product News 40

10/03/2017: Saniona obtains Research Milestone from The Michael J. Fox Foundation for Parkinsons Research of about USD 119,487 40

04/20/2017: Saniona: Saniona obtains research milestone from The Michael J. Fox Foundation for Parkinson's Research 41

Clinical Trials 42

Dec 04, 2017: Saniona Selects Preclinical Candidate in GABAA a2/a3 Program for Neuropathic Pain and Chronic Itching 42

Sep 18, 2017: Saniona reports encouraging start for tesofensine Phase 3 study 43

Aug 21, 2017: Saniona's Partner, Medix, Initiates Phase 3 Study for tesofensine in Obesity 44

Apr 12, 2017: Saniona's partner, Medix, obtains approval to initiate Phase 3 study in obesity 45

Appendix 46

Methodology 46

About GlobalData 46

Contact Us 46

Disclaimer 46


List Of Figure

List of Figures

Saniona AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Saniona AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Saniona AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Saniona AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Saniona AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Saniona AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Saniona AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Saniona AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Saniona AB, Pharmaceuticals & Healthcare, Key Facts 2

Saniona AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Saniona AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Saniona AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Saniona AB, Deals By Therapy Area, 2012 to YTD 2018 9

Saniona AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Saniona Acquires ACR325 and ACR343 Drugs from NeuroSearch 11

Saniona Acquires Assets from NeuroSearch 12

Saniona Acquires Technical Platforms from NeuroSearch 13

Aniona Acquires Portfolio of Preclinical Assets from NeuroSearch 14

Boehringer Ingelheim Enters into Research Agreement with Saniona 15

Saniona Enters into Agreement with Productos Medix 16

Saniona Enters into Agreement with Syngene 17

Saniona Extends R&D Agreement with Ataxion 18

Initiator Pharma to Raise USD2.4 Million in Rights Offering of Units 19

Scandion Oncology Raises USD0.3 Million in Private Placement of Shares 20

Saniona Raises USD4 Million in Private Placement of Shares 21

Scandion Oncology Spins-Off from Saniona 22

Initiator Pharma Raises USD2.3 Million in Rights Offering of Shares 23

Initiator Pharma Spins Out from Saniona 24

Saniona Completes IPO For USD 2.6 Million 25

Saniona to Raise USD8.7 Million in Private Placement of Bonds 26

Ataxion Acquires Ataxia Program from Saniona 27

Saniona AB, Key Competitors 28

Saniona AB, Key Employees 29

Saniona AB, Subsidiaries 30

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Saniona AB, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.